MedTrace Logo

Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel

NCT02946788 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-07-26

Study results available
· View outcomes & findings →

Summary

This is a multi center open label study intended to provide photo documentation and time to response data for BPX-01 1 and 2% minocycline topical gel for the treatment of moderate to severe non-nodular inflammatory acne vulgarism.

Conditions

  • Acne Vulgaris

Interventions

DRUG

Minocycline

BPX-01 1 or 2% topical gel will be applied to face once daily

Sponsors & Collaborators

  • BioPharmX, Inc.

    lead INDUSTRY

Principal Investigators

  • AnnaMarie Daniels · BioPharmX, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-13
Primary Completion
2018-06-01
Completion
2018-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02946788 on ClinicalTrials.gov